Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2016 - 2021)
Historic Change in Acquisitions & Divestments for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $174.0 million.
- Neurocrine Biosciences' Change in Acquisitions & Divestments fell 989.12% to $174.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $697.9 million, marking a year-over-year decrease of 700.87%. This contributed to the annual value of $967.5 million for FY2024, which is 50.39% down from last year.
- Latest data reveals that Neurocrine Biosciences reported Change in Acquisitions & Divestments of $174.0 million as of Q4 2021, which was down 989.12% from $159.7 million recorded in Q3 2021.
- Neurocrine Biosciences' 5-year Change in Acquisitions & Divestments high stood at $215.9 million for Q1 2019, and its period low was $46.9 million during Q3 2017.
- In the last 5 years, Neurocrine Biosciences' Change in Acquisitions & Divestments had a median value of $142.6 million in 2019 and averaged $139.2 million.
- Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 4880.17% in 2017, then surged by 15676.09% in 2019.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $81.9 million in 2017, then skyrocketed by 42.2% to $116.4 million in 2018, then soared by 55.42% to $180.9 million in 2019, then rose by 6.74% to $193.1 million in 2020, then decreased by 9.89% to $174.0 million in 2021.
- Its Change in Acquisitions & Divestments was $174.0 million in Q4 2021, compared to $159.7 million in Q3 2021 and $202.9 million in Q2 2021.